Iron Removal In vivo Study (IRIS)

Infections and inflammation of the eyes are becoming increasingly prevalent problems for patients

with chronic diseases or for people who use implanted eye lenses. Serious ocular infectious and

inflammatory disease can lead to significant visual disability and requires aggressive treatment

intervention to mitigate disease pathology and prevent vision loss. Preliminary work suggests that ironchelating

agents developed by Chelation Partners Incorporated can effectively control microbes and

inflammation. These excipients can enhance the power of antibiotics, especially in clinically resistant

infections, dampen inflammation and reduce the need for harsh preservatives. Studies will be designed

to: (i) evaluate the safety of the excipients, (ii) determine the ability of these agents to control

inflammatory response in the eye (iii) examine the ability of these agents to limit eye infections or their

ability to enhance the anti-microbial activity of antibiotics. Results of these studies will be valuable in

assessing the safety and efficacy of these iron-chelating agents in vivo (in animals) prior to their TOBECONTINUED

Faculty Supervisor:

Christian Lehmann;Melanie Kelly

Student:

Partner:

Chelation Partners Inc

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Dalhousie University

Program:

Accelerate

Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Government

Mitacs Partners